Leigh Purvis

@leighdrugwonk

Prescription drug policy expert in the AARP Public Policy Institute . Follow/RT ≠ endorsement. Views are my own.

Washington, D.C.
Vrijeme pridruživanja: travanj 2014.

Tweetovi

Blokirali ste korisnika/cu @leighdrugwonk

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @leighdrugwonk

  1. proslijedio/la je Tweet

    80% of prescriptions are for generics; average cost of generics is only $1 per day. That’s not the problem. Specialty drugs are only 0.5% of prescriptions but account for 25% of expenditures.

    Prikaži ovu nit
    Poništi
  2. proslijedio/la je Tweet
    28. sij

    We should address insulin affordability. However, insulin isn't the only important drug that is hard for patients to afford. Need to consider broader policies that help make high value drugs more affordable for patients.

    Poništi
  3. proslijedio/la je Tweet
    Poništi
  4. proslijedio/la je Tweet
    16. sij

    Thank you ! It was truly a gift to work with the team for my talk at . I am so grateful for your support and encouragement, this talk couldn't have come to life without all of you! 🙏🏽

    Poništi
  5. proslijedio/la je Tweet
    9. stu 2019.

    Part B premiums will be going up nearly 7% in 2020 to cover increased spending on outpatient drugs. I guess now financial toxicity is trickling down to those who aren’t taking the drugs ⁦

    Poništi
  6. proslijedio/la je Tweet

    Gooood morning Capitol Hill! Rx T. Rex is trekking across Congress today on the hunt for lower drug prices! 🦖🦖 RT if you agree: it’s time to

    Poništi
  7. proslijedio/la je Tweet

    Escorted by prescription drug-price-fighting Tyrannosaurus Rexes (known as 'Rx T. Rexs') state leaders will be on Capitol Hill tomorrow meeting with federal lawmakers & attending Health Subcommittee hearing on out-of-control Rx drug prices. !

    Poništi
  8. proslijedio/la je Tweet

    A new Rx Price Watch report shows retail drug prices have increased faster than inflation for at least 12 straight years.

    Poništi
  9. proslijedio/la je Tweet

    I support in its efforts to lower prescription drug costs. This article by shows that Pharma is getting worried and is trying to undermine the efforts by casting blame.

    Poništi
  10. 30. kol 2019.

    Multiple sclerosis drugs have been the poster child for this kind of behavior for a while but somehow I doubt it's limited to this therapeutic category...🤔

    Poništi
  11. 26. kol 2019.

    Fascinating stat demonstrating how everyone with health insurance pays for high-priced drugs: "At one point in 2018, for every hour that one of the union’s 16,000 members worked, 35 cents of his or her pay went to...the Pattersons’ prescriptions"

    Poništi
  12. proslijedio/la je Tweet
    8. kol 2019.

    We've all seen the number of patents on Humira and how many were filed after the product hit the market. Humira is not an outlier. On average, for the top 12 selling drugs in the U.S in 2017, 66% of the patents were filed after the product was for sale.

    Prikaži ovu nit
    Poništi
  13. 6. kol 2019.

    Patient charity programs are “marketing tools under the cloak of charity, more interested in the reimbursement from insurance companies than patients’ financial need.” via

    Poništi
  14. proslijedio/la je Tweet
    2. kol 2019.

    Last week I was invited to submit a letter for the Congressional hearing called The Patient Perspective: The Devastating Impacts of Skyrocketing Drug Prices on American Families. I'm going to share a few of my thoughts in the next few tweets.

    Prikaži ovu nit
    Poništi
  15. proslijedio/la je Tweet
    27. lip 2019.

    The future is in doubt for cheaper versions of injected drugs known as biosimilars, reports , with insights from :

    Poništi
  16. proslijedio/la je Tweet
    29. svi 2019.
    Poništi
  17. proslijedio/la je Tweet
    16. svi 2019.

    "Because of patent thickets, AbbVie has been able to maintain a monopoly on its arthritis drug, Humira, earning $583 every second the company maintains its monopoly in keeping a more affordable generic version off the market."

    Poništi
  18. proslijedio/la je Tweet

    This quote by is sad but true. As someone who believes in the mission & value of pharma R&D, I find the industry’s lack of self-restraint on pricing, patents, marketing, etc. in the name of “boosting shareholder value” deeply disappointing.

    Prikaži ovu nit
    Poništi
  19. 17. svi 2019.
    Poništi
  20. 4. tra 2019.

    ⁦⁦Our latest Rx Price Watch report found that the average annual cost for one brand name drug is over 18x higher than the average annual cost for a generic drug ⁦⁩ ⁦

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·